Cotización Perspective Therapeutics - CATX

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

3.41

Postura de Compra

Postura de Venta

Volume Operado de la Acción

0.00 Rango del Día 0.00

2.70 Rango de 52 semanas 19.05

Capitalización de Mercado [m]

230.474M

Precio Anterior

3.41

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

1,684,379

Acciones en circulación

67,587,540

Rendimiento del Dividendo

Ratio Precio/Utilidad

-4.96

Beneficio por acción (BPA)

-0.69

turnover

1.43M

Beneficio neto

-46.51M

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers incl... Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. Mostrar más

Sector

Eating Places

Industria

Surgical,med Instr,apparatus

Sitio web

perspectivetherapeutics.com

Sede

Wilmington, Delaware, USA

Fundado

1983

Perspective Therapeutics Inc is listed in the Eating Places sector of the American Stock Exchange with ticker CATX. The last closing price for Perspective Therapeutics was US$3.41. Over the last year, Perspective Therapeutics shares have traded in a share price range of US$ 2.70 to US$ 19.05.

Perspective Therapeutics currently has 67,587,540 shares in issue. The market capitalisation of Perspective Therapeutics is US$230.47 million. Perspective Therapeutics has a price to earnings ratio (PE ratio) of -4.96.

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Form 8-K - Current report

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of...

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Form 8-K - Current report

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its...

Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.41	-10.7329842932	3.82	3.91	3.2206	584111	3.44589275	CS
4	-0.07	-2.01149425287	3.48	4.24	3.02	1012464	3.52590472	CS
12	-5.52	-61.8141097424	8.93	8.93	2.7	1684379	3.70994262	CS
26	-9.27	-73.1072555205	12.68	16.55	2.7	1188582	7.3565083	CS
52	-5.309	-60.8900103223	8.719	19.05	2.7	2517750	12.21416991	CS
156	-0.353	-9.38081318097	3.763	19.05	2.05	1702953	10.42524389	CS
260	-0.353	-9.38081318097	3.763	19.05	2.05	1702953	10.42524389	CS

CATX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Perspective Therapeutics?

El precio actual de las acciones de Perspective Therapeutics es US$ 3.41

¿Cuántas acciones de Perspective Therapeutics están en circulación?

Perspective Therapeutics tiene 67,587,540 acciones en circulación

¿Cuál es la capitalización de mercado de Perspective Therapeutics?

La capitalización de mercado de Perspective Therapeutics es USD 230.47M

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Perspective Therapeutics?

Perspective Therapeutics ha negociado en un rango de US$ 2.70 a US$ 19.05 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Perspective Therapeutics?

El ratio precio/beneficio de Perspective Therapeutics es -4.96

¿Cuál es el ratio de efectivo a ventas de Perspective Therapeutics?

El ratio de efectivo a ventas de Perspective Therapeutics es 160.85

¿Cuál es la moneda de reporte de Perspective Therapeutics?

Perspective Therapeutics presenta sus resultados financieros en USD

¿Cuál es el último ingresos anual de Perspective Therapeutics?

El último ingresos anual de Perspective Therapeutics es USD 1.43M

¿Cuál es el último beneficio anual de Perspective Therapeutics?

El último beneficio anual de Perspective Therapeutics es USD -46.51M

¿Cuál es la dirección registrada de Perspective Therapeutics?

La dirección registrada de Perspective Therapeutics es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

¿Cuál es la dirección del sitio web de Perspective Therapeutics?

La dirección del sitio web de Perspective Therapeutics es perspectivetherapeutics.com

¿En qué sector industrial opera Perspective Therapeutics?

Perspective Therapeutics opera en el sector SURGICAL,MED INSTR,APPARATUS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
SIMGrupo Simec SAB de CV	US$ 41.85 (58.94%)	71
EPEmpire Petroleum Corporation	US$ 7.90 (33.22%)	14
VINEFresh Vine Wine Inc	US$ 0.7922 (14.10%)	7.96k
DCDakota Gold Corp	US$ 2.85 (13.55%)	16.67k
LEUCentrus Energy Corporation	US$ 91.77 (12.17%)	1.91k
ATMPiPath Select MLP ETN	US$ 22.01 (-27.74%)	6
SVTServotronics Inc	US$ 8.01 (-26.48%)	1
LGLLGL Group Inc	US$ 5.01 (-25.89%)	2
AMBIAmbipar Emergency Response	US$ 4.11 (-22.01%)	1
INFUInfuSystems Holdings Inc	US$ 6.91 (-14.16%)	2
ETHU2x Ether ETF	US$ 4.62 (1.54%)	711.59k
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 27.71 (0.07%)	683.6k
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3.115 (1.80%)	532.65k
FXIiShares China Large Cap	US$ 32.86 (1.80%)	478.19k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 2.745 (3.20%)	312.27k